Resources
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 1049
Aftershocks Roundtable: How do we rebuild our HIV and public health infrastructure?
Please join TCA and IAPAC’s Dr. José M. Zuniga – author of the new book “Aftershocks: Trump 2.0, Public Health, and Our Better Angels” – and a dynamic panel to discuss the profound disruption of public health systems over the past almost...
AVAC’s Remarks to the NIAID Council and the ARAC on the proposed NIAID reorganization
AVAC delivered a public comment for the record at the NIAID Council meeting raising concerns about the proposed NIAID reorganization and its potential impact on HIV research, including the elimination of the Division of Clinical Research, disruption...
Artificial Intelligence in the HIV response: All the good stuff from AIDS2026
An analysis by Jirair Ratevosian of the Duke Global Health Institute looked comprehensively at AI-related abstracts, key themes from use cases, and emerging trends at AIDS 2026. His review shows the potential of AI to support HIV testing and prevention, including PrEP, and improve linkages to care and services, particularly in sub-Saharan Africa. “AI is becoming a new front door to HIV services,” he writes, but the analysis also shows that while most of the research was focused on feasibility and pilot implementation of AI, a significant evidence gap around health outcomes, as well as privacy, community engagement, and governance remains. He concludes that: AI is working, but trust is what makes or breaks the product; specialized tools beat generics; human-in-the-loop is becoming standard; the field needs to move from pilots to proof of outcomes; and scale depends on systems, not just models.
AVAC Comment on Proposed Reorganization of the National Institutes of Allergy and Infectious Diseases (NIAID)
In response to the National Institute of Health’s (NIH) proposed reorganization of the National Institutes of Allergy and Infectious Diseases (NIAID), AVAC submitted comment to the Office of the Director of the NIH. Citing concerns of dismantling a currently unified trial oversight and support system, disruptions to trial site readiness and impacts on community engagement, and delays in funding and clinical trials, AVAC urged NIH leadership to meaningfully consider the recommendations of AVAC and many allied public health partners on the proposed restructuring.
Combo bNAbs for HIV Prevention – Latest Developments
Please join AVAC for a global webinar: Combo bNAbs for HIV Prevention – Latest Developments. Broadly neutralizing antibodies (bNAbs) remain at the center of research toward an HIV vaccine and immune-based HIV prevention. In particular, researchers...
EXPrESSIVE-11 Communications Toolkit
Downloadable materials to foster community interest, awareness and engagement in the EXPrESSIVE-11 trials, tailored to the local languages and reflecting the lived realities of communities in Argentina, Brazil, broader Latin America, Kenya,...
Plain Language as Scientific Accountability: How to Communicate Science Beyond Academic Audiences
This joint UW/Fred Hutch—Penn CFAR session brings the two CFARs together in conversation around how we communicate science beyond academic audiences. This session will present examples of technical language from HIV cure, prevention, and treatment...
Prevention Option:
Harnessing Artificial Intelligence for HIV: Breakthrough or Buzzword?
This presentation by Izukanji Sikazwe, Head of HIV at The Global Fund, during AIDS 2026 explores how the field might harness artificial intelligence in response to HIV. Sikazwe unpacks what AI must be, what we must build, and the promise of AI in HIV programming.
Prevention Option:
Lenacapavir Regulatory Approval
Regulatory approvals, pending decisions, and appeals as of August 2026.
Prevention Option:
From Research to Access: The Community Statement from the Global Community Advisory Group (GCAG) on the Future of Alima (Alimatravir) for HIV Prevention
The EXPrESSIVE-10 Global Community Advisory Group (GCAG) released a statement on the future of alimatravir and HIV prevention. The statement reflects community perspectives and priorities around prevention choice, meaningful community engagement, equitable access, and ensuring that communities have a voice as research progresses toward potential introduction. As the GCAG writes, “The test is now whether early planning can translate into faster, more equitable action. An access plan is valuable not because it is announced, but because it creates a pathway that can be tracked, challenged, and delivered.”
Prevention Option:
showing 1-10 of 1049